{
  "schemaVersion": 1,
  "id": "research-383",
  "slug": "383-what-the-lowest-recorded-weight-adds-to-a-three-year-analysis",
  "title": "What the lowest recorded weight adds to a three-year analysis",
  "catalogLabel": "TIRZ GLP-2",
  "productCollection": "https://heritagebiolabs.com/research-library/products/tirz-glp-2",
  "productHandles": [
    "tirz-glp-2-692"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/tirz-glp-2-692"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 319,
  "sourceYears": [
    2022,
    2026
  ],
  "paragraphs": [
    "A peptide is a short chain of amino acids held together by peptide bonds. Some can engage receptors that influence appetite and glucose regulation. Tirzepatide acts at GIP and GLP-1 receptors. The “TIRZ GLP-2” catalog wording refers to tirzepatide rather than the GLP-2 receptor. A 2026 analysis explored how much weight participants regained from their lowest recorded weight while they remained in a long-term study. [1, 2]",
    "The lowest recorded value is called a weight nadir. It is a different point of reference from starting weight. A person can be above their lowest measured weight and still be below where they started. Looking at change from the nadir allowed investigators to describe part of the path between the starting and final measurements. [1]",
    "The researchers used data from the three-year SURMOUNT-1 trial. Their analysis selected participants with prediabetes at the start who met the study’s definition of adherence to tirzepatide and reached at least a 5% reduction from their baseline weight. By week 176, about 70% of this selected group had regained less than 5% from their recorded nadir. About 22% were in the next regain category and 8% in the largest category. The analysis also examined glucose category and waist-to-height ratio at the end of the study. [1]",
    "The selection rules are essential to interpreting the percentages. The report does not describe everyone who began tirzepatide, everyone who stopped, or people who never reached the weight threshold. The study also divided participants into groups based on weight regain that had already occurred. Those groups were defined by observed outcomes, rather than assigned by chance. [1]",
    "This approach helps describe variation over time among people who met the analysis criteria. It provides information that would be missing from a simple comparison of starting and final weights. It cannot determine where a future individual’s lowest weight will be or how their measurements will change after the end of follow-up. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Louis J. Aronne et al. Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes. Obesity Pillars (publication 2026-09-18).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42831032/"
    },
    {
      "number": 2,
      "citation": "Bingfa Sun et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences (publication 2022-03-25).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35333651/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/383-what-the-lowest-recorded-weight-adds-to-a-three-year-analysis",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/383-what-the-lowest-recorded-weight-adds-to-a-three-year-analysis.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/383-what-the-lowest-recorded-weight-adds-to-a-three-year-analysis.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 077 - Thymosin Alpha-1 and TIRZ GLP-2.docx",
    "sourceArticleNumber": 383,
    "contentSha256": "0c5517d58ff890ba3f2bd72ba4c011ac1a9cea210192f5a45b843e309851ea3d",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
